---
title: "Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies"
description: "This phase 1 trial studies the side effects and the best dose of donor CD8+ memory T-cells in treating patients with hematolymphoid malignancies. Giving lo"
url: "https://www.clareohealth.com/clinical-trials/NCT01523223"
---

This phase 1 trial studies the side effects and the best dose of donor CD8+ memory T-cells in treating patients with hematolymphoid malignancies. Giving low dose of chemotherapy before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-cancer effects). Giving an infusion of the donor's T cells (donor lymphocyte infusion) after the transplant may help increase this effect

## Key Facts

**ID:** NCT01523223
**Status:** COMPLETED
**Phase:** PHASE1
**Type:** INTERVENTIONAL
**Enrollment:** 16
**Sponsor:** Robert Lowsky

## About This Study

This clinical trial is testing a new treatment involving donor CD8+ memory T-cells for patients with certain blood cancers who have had a stem cell transplant but are experiencing a relapse. It aims to see how safe this treatment is and what the best dose might be.

## Detailed Description

PRIMARY OBJECTIVES: I. To determine the feasibility of purifying allogeneic CD8+ memory T-cells suitable for clinical application and to determine the safety and maximum tolerated dose (MTD) of these cells in patients with recurrent or refractory hematolymphoid malignancies following allogeneic hematopoietic cell transplant (HCT). SECONDARY OBJECTIVES: I. To determine disease response, time to disease progression, event-free survival, and overall survival following treatment with allogeneic CD8+ memory T-cells. II. To assess donor specific chimerism before and at designated time points after treatment with allogeneic CD8+ memory T-cells. OUTLINE: This is a dose-escalation study. Patients undergo CD8+ memory T-cell infusion over 10 to 20 minutes.

## Conditions

- Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
- Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
- Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
- Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
- Adult Nasal Type Extranodal NK/T-cell Lymphoma
- Cutaneous B-cell Non-Hodgkin Lymphoma
- Extranodal Marginal Zone B-cell Lymphoma
- Hepatosplenic T-cell Lymphoma
- Intraocular Lymphoma
- Nodal Marginal Zone B-cell Lymphoma
- Peripheral T-cell Lymphoma
- Recurrent Adult Acute Lymphoblastic Leukemia
- Recurrent Adult Acute Myeloid Leukemia
- Recurrent Adult Burkitt Lymphoma
- Recurrent Adult Diffuse Large Cell Lymphoma
- Recurrent Adult Diffuse Mixed Cell Lymphoma
- Recurrent Adult Diffuse Small Cleaved Cell Lymphoma
- Recurrent Adult Grade III Lymphomatoid Granulomatosis
- Recurrent Adult Hodgkin Lymphoma
- Recurrent Adult Immunoblastic Large Cell Lymphoma
- Recurrent Adult Lymphoblastic Lymphoma
- Recurrent Adult T-cell Leukemia/Lymphoma
- Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma
- Recurrent Grade 1 Follicular Lymphoma
- Recurrent Grade 2 Follicular Lymphoma
- Recurrent Grade 3 Follicular Lymphoma
- Recurrent Mantle Cell Lymphoma
- Recurrent Marginal Zone Lymphoma
- Recurrent Mycosis Fungoides/Sezary Syndrome
- Recurrent Small Lymphocytic Lymphoma
- Refractory Chronic Lymphocytic Leukemia
- Relapsing Chronic Myelogenous Leukemia
- Splenic Marginal Zone Lymphoma
- Waldenstrom Macroglobulinemia

## Interventions

**BIOLOGICAL: therapeutic allogeneic lymphocytes**
Undergo CD8 memory T-cell infusion

## Eligibility

Inclusion Criteria: * Patients must have undergone a human leukocyte antigen (HLA) matched (sibling) allogeneic HCT for a hematologic or lymphoid malignancy other than chronic mye…

## Who Can Participate

**Minimum age:** 18

**Maximum age:** 75

**Sex:** ALL

**Accepts healthy volunteers:** No

## Study Locations

- Stanford University, Stanford, California, United States

## Contact Information

## Important Dates

**Study start:** January 1, 2012

**Completion date:** October 1, 2016

**Last updated:** November 22, 2023

## Collaborators

- National Cancer Institute (NCI)

## Consider Discussing with Your Care Team

### Worth Discussing If

- You have had a stem cell transplant and your blood cancer has come back.
- Your doctor has mentioned the possibility of using donor T-cells to help fight your cancer.
- You are between the ages of 18 and 75 and are looking for additional treatment options.

### Questions to Ask

- What are the potential side effects of the CD8+ memory T-cell infusion?
- How does this treatment compare to other options I have?
- What is the expected timeline for treatment and recovery?
- Are there any specific eligibility criteria I should be aware of?
- How will my progress be monitored during and after the treatment?
- What happens if the treatment does not work?

[View on ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT01523223)
